共 50 条
- [21] Significant in vivo activity of ENMD-2076, a novel inhibitor of Aurora receptor tyrosine kinases, alone and in combination with lenalidomide against plasma cell myelomaCANCER RESEARCH, 2011, 71Sandusky, George E.Rodgers, MattZhang, ShuHongSinn, AnthonyPollok, KarenFarag, Sherif
- [22] Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft ModelsCLINICAL CANCER RESEARCH, 2010, 16 (11) : 2989 - 2998Tentler, John J.Bradshaw-Pierce, Erica L.Serkova, Natalie J.Hasebroock, Kendra M.Pitts, Todd M.Diamond, Jennifer R.Fletcher, Graham C.Bray, Mark R.Eckhardt, S. Gail
- [23] Profiling of syngeneic models by anti-PD1, PD-L1 and CTLA4 immunotherapeutics and RNAseq analysis provide predictive biomarkers for cancer immunotherapyEUROPEAN JOURNAL OF CANCER, 2015, 51 : S27 - S27Zhang, L.Zhang, J.Shi, Q.
- [24] Significant in vivo activity of ENMD-2076, a novel multi-targeted kinase inhibitor, towards xenograft models of human hepatocellular carcinomasMOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)Yin, PeipeiLu, HongqiBray, Mark R.Li, BingshengRen, Ken
- [25] Antitumor activity of lenvatinib in combination with everolimus or an anti-PD1 antibody in preclinical RCC modelsCANCER RESEARCH, 2018, 78 (13)Adachi, YusukeKimura, TakayukiMatsuki, MasahiroMatsui, JunjiFunahashi, Yasuhiro
- [26] Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast CancerFRONTIERS IN ONCOLOGY, 2017, 7Ionkina, Anastasia A.Tentler, John J.Kim, JihyeCapasso, AnnaPitts, Todd M.Ryall, Karen A.Howison, Rebekah R.Kabos, PeterSartorius, Carol A.Tan, Aik ChoonEckhardt, S. GailDiamond, Jennifer R.
- [27] A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerBreast Cancer Research, 20Jennifer R. DiamondS. G. EckhardtTodd M. PittsAdrie van BokhovenDara AisnerDaniel L. GustafsonAnna CapassoSharon SamsPeter KabosKathryn ZolmanTiffany ColvinAnthony D. EliasAnna M. StornioloBryan P. SchneiderDexiang GaoJohn J. TentlerVirginia F. BorgesKathy D. Miller
- [28] Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapyJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Dearden, Helen ClareAu, LewisWang, Daniel YingZimmer, LisaEroglu, ZeynepSmith, Jessica LouiseCurvietto, MarcelloKhoo, ChloeAtkinson, VictoriaLo, SerigneGuminski, AlexanderLong, Georgina V.Sandhu, Shahneen KaurAscierto, Paolo AntonioCarlino, Matteo S.Johnson, Douglas BucknerLarkin, James M. G.Menzies, Alexander M.
- [29] A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerBREAST CANCER RESEARCH, 2018, 20Diamond, Jennifer R.Eckhardt, S. G.Pitts, Todd M.van Bokhoven, AdrieAisner, DaraGustafson, Daniel L.Capasso, AnnaSams, SharonKabos, PeterZolman, KathrynColvin, TiffanyElias, Anthony D.Storniolo, Anna M.Schneider, Bryan P.Gao, DexiangTentler, John J.Borges, Virginia F.Miller, Kathy D.
- [30] A novel multi-targeted Aurora A and VEGFR2 kinase inhibitor, ENMD-2076, demonstrates synergistic antiproliferative and proapoptotic effects in combination with chemotherapy and trastuzumab in breast cancer cell linesMOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)Diamond, Jennifer R.Eckhardt, S. GailPitts, Todd M.Britt, Blair C.Kachaeva, Maria I.Varella-Garcia, MarileilaBray, Mark R.Fletcher, Graham C.Tentler, John J.